Kamili Saleem, Sozzi Vitini, Thompson Geoff, Campbell Katie, Walker Christopher M, Locarnini Stephen, Krawczynski Krzysztof
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Hepatology. 2009 May;49(5):1483-91. doi: 10.1002/hep.22796.
Hepatitis B virus (HBV) mutants resistant to treatment with nucleoside or nucleotide analogs and those with the ability to escape from HBV-neutralizing antibody have the potential to infect HBV-vaccinated individuals. To address this potential serious public health challenge, we tested the efficacy of immunity induced by a commercial hepatitis B vaccine against a tissue culture-derived, clonal HBV polymerase mutant in HBV seronegative chimpanzees. The polymerase gene mutant contained a combination of three mutations (rtV173L, rtL180M, rtM204V), two of which resulted in changes to the overlapping viral envelope of the hepatitis B surface antigen (sE164D, sI195M). Prior to the HBV mutant challenge of vaccinated chimpanzees, we established virologic, serologic, and pathologic characteristics of infections resulting from intravenous inoculation of the HBV polymerase gene mutant and the sG145R vaccine-escape surface gene mutant. Cloning and sequencing experiments determined that the three mutations in the polymerase gene mutant remained stable and that the single mutation in the surface gene mutant reverted to the wild-type sequence. Immunological evidence of HBV replication was observed in the vaccinated chimpanzees after challenge with the polymerase gene mutant as well as after rechallenge with serum-derived wild-type HBV (5,000 chimpanzee infectious doses administered intravenously), despite robust humoral and cellular anti-HBV immune responses after hepatitis B vaccination.
Our data showing successful experimental infection by HBV mutants despite the presence of high anti-HBs levels considered protective in the vaccinated host are consistent with clinical reports on breakthrough infection in anti-HBs-positive patients infected with HBV mutants. In the absence of a protective humoral immunity, adaptive cellular immune responses elicited by infection may limit HBV replication and persistence.
对核苷或核苷酸类似物治疗耐药以及具有逃避乙肝病毒中和抗体能力的乙肝病毒(HBV)突变体有可能感染已接种乙肝疫苗的个体。为应对这一潜在的严重公共卫生挑战,我们在乙肝血清阴性的黑猩猩中测试了一种商用乙肝疫苗诱导的免疫对一种源自组织培养的克隆HBV聚合酶突变体的效力。该聚合酶基因突变体包含三个突变(rtV173L、rtL180M、rtM204V)的组合,其中两个导致乙肝表面抗原重叠病毒包膜发生变化(sE164D、sI195M)。在对接种疫苗的黑猩猩进行HBV突变体攻击之前,我们确定了静脉接种HBV聚合酶基因突变体和sG145R疫苗逃逸表面基因突变体所导致感染的病毒学、血清学和病理学特征。克隆和测序实验确定聚合酶基因突变体中的三个突变保持稳定,表面基因突变体中的单个突变回复为野生型序列。在用聚合酶基因突变体攻击后以及用血清来源的野生型HBV再次攻击后(静脉注射5000个黑猩猩感染剂量),在接种疫苗的黑猩猩中观察到了HBV复制的免疫学证据,尽管乙肝疫苗接种后有强大的体液和细胞抗HBV免疫反应。
我们的数据显示,尽管接种疫苗的宿主中存在被认为具有保护作用的高抗-HBs水平,但HBV突变体仍能成功进行实验性感染,这与关于感染HBV突变体的抗-HBs阳性患者发生突破性感染的临床报告一致。在缺乏保护性体液免疫的情况下,感染引发的适应性细胞免疫反应可能会限制HBV的复制和持续存在。